We have collected information about New Drug Delivery Strategies For Improved Parkinson Disease Therapy for you. Follow the links to find out details on New Drug Delivery Strategies For Improved Parkinson Disease Therapy.
https://www.researchgate.net/publication/24345076_New_drug_delivery_strategies_for_improved_Parkinson's_disease_therapy
New drug delivery strategies for improved Parkinson's disease therapy Article · Literature Review (PDF Available) in Expert Opinion on Drug Delivery 6(4):389-404 · May 2009 with 1,067 Reads
https://www.tandfonline.com/doi/abs/10.1517/17425240902870405
Nov 29, 2013 · New drug delivery strategies for improved Parkinson's disease therapy. ... New drug delivery strategies for improved Parkinson's disease therapy ... This review provides an overview of progress in anti-Parkinson therapy, mainly focused on delivery strategies and codrug approach for treatment of this neurological disorder.Author: Antonio Di Stefano, Piera Sozio, Antonio Iannitelli, Laura Serafina Cerasa
http://europepmc.org/abstract/MED/19382882
May 01, 2009 · Furthermore, the authors examine a series of new LD codrugs and non-dopaminergic drugs for Parkinson's disease treatment, together with a variety of experimental delivery strategies including transdermal therapeutic systems, liposomes, solid …Author: Antonio Di Stefano, Piera Sozio, Antonio Iannitelli, Laura Serafina Cerasa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238398/
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease) ... Iannitelli A, Cerasa LS. New drug delivery strategies for improved Parkinson’s disease therapy. Expert Opinion on Drug ... Sahni JK, Baboota S, Ali J. New non-oral drug delivery systems for Parkinson's disease ...Author: Carlos Spuch, Carmen Navarro
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153272/
Dec 07, 2016 · Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment. ... lactoferrin-modified PEG-PLGA nanoparticles, brain targeting, intranasal ... Iannitelli A, Cerasa LS. New drug delivery strategies for improved Parkinson’s disease therapy. Expert Opin Drug Deliv. 2009; 6 (4 ...Author: Chenchen Bi, Aiping Wang, Yongchao Chu, Sha Liu, Hongjie Mu, Wanhui Liu, Zimei Wu, Kaoxiang Sun, You...
https://www.researchgate.net/publication/49829674_New_non-oral_drug_delivery_systems_for_Parkinson's_disease_treatment
Conclusion: Nanotechnology and nanosized drug delivery systems are being investigated intensely and could have potential effect for Parkinson’s disease. The improvement of drug delivery systems ...
https://www.mdedge.com/neurology/article/170943/parkinsons-disease/strategies-treating-motor-fluctuations-parkinsons
Improved delivery of levodopa and new therapies may help to reduce off time. Neurology Reviews . 2018 August;26(8):32 MIAMI —Motor fluctuations in Parkinson’s disease can arise from more than one cause, and a clinician needs to consider a range of possibilities.
https://www.tandfonline.com/doi/abs/10.1517/17425247.2011.556616
Aug 06, 2017 · Areas covered: This review highlights a variety of new non-oral drug delivery strategies for non-invasive and invasive routes of drug administration for the treatment of PD. It also includes current and future trends of liposomes, solid lipid nanoparticles and biocompatible microparticles as new non-oral drug delivery systems.Author: Shadab, Shadabul Haque, Jasjeet Kaur Sahni, Sanjula Baboota, Javed Ali
https://www.sciencedirect.com/science/article/pii/S0168365915002138
Exosomes as drug delivery vehicles for Parkinson's disease therapy Author links open overlay panel Matthew J. Haney a b Natalia L. Klyachko a b c Yuling Zhao a b Richa Gupta a b Evgeniya G. Plotnikova c Zhijian He a b Tejash Patel b Aleksandr Piroyan a b Marina Sokolsky a b Alexander V. Kabanov a b c Elena V. Batrakova a bAuthor: Matthew J. Haney, Natalia L. Klyachko, Natalia L. Klyachko, Yuling Zhao, Richa Gupta, Evgeniya G. Pl...
https://onlinelibrary.wiley.com/doi/10.1002/mds.20457
The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. ... , New drug delivery strategies for improved Parkinson's disease therapy, Expert Opinion on Drug ...Author: C. Warren Olanow, Joseph Jankovic
Searching for New Drug Delivery Strategies For Improved Parkinson Disease Therapy?
You can just click the links above. The data is collected for you.
